MTOR and nonpapillary renal cell carcinoma: These strategies could be combined with allosteric mTOR inhibition; however, while rapalogs do not benefit all patients and do not always produce durable responses, immunotherapy with checkpoint inhibitors is becoming a major choice for the treatment of ccRCC [41].